The FDA has extended the review period for its supplemental biologics license application of Leqembi Iqlik by three months to Aug. 24.
NEW YORK – Sensei Biotherapeutics announced this week that it has dosed the first patient in a Phase Ib/II trial evaluating a combination regimen of the mTOR1/2 inhibitor sapanisertib and the ...
NEW YORK – Roswell Park Comprehensive Cancer Center is starting a Phase II trial of a peptide vaccine for neuroendocrine tumors in combination with MimiVax, a Roswell spinout. The study will examine ...
NEW YORK – ParcelBio on Thursday debuted as a new company developing mRNA therapies. The San Francisco-based biotech launched with $13 million in seed funding led by Breyer Capital. Other investors ...
NEW YORK – Pierre Fabre Pharmaceuticals said on Thursday that it will resubmit its biologics license application (BLA) for the allogenic T-cell immunotherapy Ebvallo (tabelecleucel) following a ...
The agency's acceptance was based on results from the Phase III OptiTROP-Lung05 study, which met its primary endpoint of progression-free survival.
NEW YORK – Six years after its first precision medicine adoption survey in 2020, a new report from the University of Pittsburgh Medical Center (UPMC) and the University of Pittsburgh found that ...
NEW YORK – Revolution Medicines is preparing for the potential approval of its first product, daraxonrasib, in pancreatic cancer as it positions other pipeline assets for pivotal studies. The firm ...
The company looked externally for cell therapy and ADC additions to its pipeline last quarter, keeping internal R&D spending ...
The firm will focus on encouraging physicians to prescribe the combination therapy for ovarian cancer patients at first recurrence.
The FDA granted a Commissioner's National Priority Voucher to accelerate the review of the treatment, which was submitted for approval last month.
InVimmune will first focus development efforts in oncology, where the firms say unmet need remains high. To that end, the company has established an oncology scientific advisory board that includes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results